BRISTOL-MYERS SQUIBB COMPANY Business Combination, Acquisition Related Costs
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Business Combination, Acquisition Related Costs of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2022-02-09
- BRISTOL-MYERS SQUIBB COMPANY business combination, acquisition related costs for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY business combination, acquisition related costs for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY business combination, acquisition related costs for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY business combination, acquisition related costs for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY business combination, acquisition related costs for fiscal 2021 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY business combination, acquisition related costs for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- BRISTOL-MYERS SQUIBB COMPANY business combination, acquisition related costs for fiscal 2019 was $657.00M.
- BRISTOL-MYERS SQUIBB COMPANY business combination, acquisition related costs for fiscal 2018 was $0.00.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 3 month as first filed | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-09 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $0.00 derived: sum of 2 quarters · filed 2022-02-09 | $0.00 derived: sum of 3 quarters · filed 2022-02-09 | $0.00 10-K · filed 2022-02-09 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $182.00M derived: sum of 4 quarters · filed 2022-02-09 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $182.00M derived: sum of 3 quarters · filed 2022-02-09 | $189.00M derived: sum of 4 quarters · filed 2022-02-09 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $182.00M derived: sum of 2 quarters · filed 2022-02-09 | $189.00M derived: sum of 3 quarters · filed 2022-02-09 | $492.00M derived: sum of 4 quarters · filed 2022-02-09 | |
| 2019-12-31 | $182.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $189.00M derived: sum of 2 quarters · filed 2022-02-09 | $492.00M derived: sum of 3 quarters · filed 2022-02-09 | $657.00M 10-K · filed 2022-02-09 | |
| 2019-09-30 | $7.00M 10-Q · filed 2020-11-05 | $310.00M derived: sum of 2 quarters · filed 2020-11-05 | $475.00M 10-Q · filed 2020-11-05 | $475.00M derived: sum of 4 quarters · filed 2021-02-10 | |
| 2019-06-30 | $303.00M 10-Q · filed 2020-08-06 | $468.00M 10-Q · filed 2020-08-06 | $468.00M derived: sum of 3 quarters · filed 2021-02-10 | $468.00M derived: sum of 4 quarters · filed 2021-02-10 | |
| 2019-03-31 | $165.00M 10-Q · filed 2020-05-07 | $187.00M 10-Q · filed 2019-04-25 | $165.00M derived: sum of 2 quarters · filed 2021-02-10 | $165.00M derived: sum of 3 quarters · filed 2021-02-10 | $165.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $0.00 derived: sum of 2 quarters · filed 2021-02-10 | $0.00 derived: sum of 3 quarters · filed 2021-02-10 | $0.00 10-K · filed 2021-02-10 | |
| 2018-09-30 | $0.00 10-Q · filed 2019-10-31 | $0.00 derived: sum of 2 quarters · filed 2019-10-31 | $0.00 10-Q · filed 2019-10-31 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-07-25 | $0.00 10-Q · filed 2019-07-25 | |||
| 2018-03-31 | $0.00 10-Q · filed 2019-04-25 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |